Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24‐hour continuously monitored mean glucose and fasting β‐hydroxybutyrate levels in a phase IIa pilot study
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Aims: To investigate the effects of total daily insulin dose ( TDD ) reductions on 24‐hour continuously monitored mean glucose and fasting β‐hydroxybutyrate (a marker for diabetic ketosis/ketoacidosis [ DKA ]) levels, using patient‐level data from a 14‐day, pilot study of dapagliflozin in type 1 diabetes ( T1DM ). Methods: A post hoc exploratory correlation analysis was performed to determine the relationship between change in TDD and (1) 24‐hour mean glucose, assessed by continuous glucose monitoring, and (2) fasting β‐hydroxybutyrate, in 70 patients with T1DM receiving insulin and dapagliflozin (1, 2.5, 5 or 10 mg) or placebo. The pharmacodynamic effect of dapagliflozin was estimated as a virtual “insulin dose” using 24‐hour urinary glucose excretion values and a recognized insulin‐to‐carbohydrate counting technique. Results: Trends for correlations were observed between change in TDD and 24‐hour glucose (day 7: r = −0.264, P = .056) and β‐hydroxybutyrate (day 7: r = −0.187, P = .133; day 14: r = −0.274, P = .047). The pharmacodynamic effect of dapagliflozin 5 or 10 mg was estimated as equivalent to ~20% of baseline TDD . Higher mean and maximum β‐hydroxybutyrate levels were observed on days 7 and 14 in patients with a TDD reduction >20% vs ≤20%. Conclusions: Over 14 days, decreasing the insulin dose diminished the glucose‐lowering effect of dapagliflozin–insulin combination therapy and increased levels of β‐hydroxybutyrate. While insulin dose adjustments should always be individualized, these analyses suggest that, as a general rule, TDD reduction in dapagliflozin‐treated patients with T1DM should not exceed 20%, to ensure glycaemic control does not deteriorate and to mitigate the potential for an increased risk of DKA .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · cited 1×
“adults with T1DM in the USA do not achieve target glycated haemoglobin (HbA1c) <7% (<53 mmol/mol).(4) This might be attributable to a variety of factors, including fear of hypoglycaemia.”
BackgroundCV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Rosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664 · cited 1×
“In addition, regardless of blood glucose and insulin, guidance from regulatory authorities suggests that monitoring of ketones should be considered in patients receiving an SGLT2 inhibitor who feel unwell or who display symptoms of DKA, and in clinical situations known to predispose patients to ketoacidosis (eg, reduc…”
BackgroundUpdate on developments with SGLT2 inhibitors in the management of type 2 diabetes
Nauck, M. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s50773 · Cited by 343
Polidori, D., Sanghvi, A., Seeley, R. J., & Hall, K. D. (2016) · Obesity · doi:10.1002/oby.21653 · Cited by 209
Peters, A. L., Henry, R. R., Thakkar, P., Tong, C., & Alba, M. (2016) · Diabetes Care · doi:10.2337/dc15-1995 · Cited by 106
Self-citationMonnier, L., & Colette, C. (2009) · Diabetes Care · doi:10.2337/dc09-s310 · Cited by 82
Cited by
Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Griffen, S. C., Tschöpe, D., Thorén, F., Xu, J., Langkilde, A. M., Proietto, J., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30308-x · Cited by 293
Self-citationMathieu, C., Dandona, P., Gillard, P., Senior, P., Hasslacher, C., Araki, E., Lind, M., Bain, S. C., Jabbour, S., Arya, N., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0623 · Cited by 252
“tion of adjunct dapagliflozin therapy (14,16,18,19) and subsequent caution in insulin dose reduction during treatment may be important to mitigate the risk of DKA.”
BackgroundSelf-citationYamada, T., Shojima, N., Noma, H., Yamauchi, T., & Kadowaki, T. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13260 · Cited by 81
Musso, G., Sircana, A., Saba, F., Cassader, M., & Gambino, R. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003461 · Cited by 61
Metadata
- Authors
- Henry, R. R., Dandona, P., Pettus, J., Mudaliar, S., Xu, J., & Hansen, L.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-03-27
- Volume
- 19
- Issue
- 6
- Pages
- 814-821
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2579350152
- Cited by
- 42
- References
- 8
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24‐hour continuously monitored mean glucose and fasting β‐hydroxybutyrate levels in a phase IIa pilot study. https://app.cochat.ai/papers/10.1111/dom.12882
- The paper
- Henry, R. R., Dandona, P., Pettus, J., Mudaliar, S., Xu, J., & Hansen, L. (2017). Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24‐hour continuously monitored mean glucose and fasting β‐hydroxybutyrate levels in a phase IIa pilot study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12882
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.